This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Bacterial infection	Not applicable	<p>Rodent and <i>in vitro</i> studies identified fluorocyclines that could help treat bacterial infections. In multiple panels of tetracycline-sensitive and -resistant bacterial strains, fluorocycline compounds showed antibiotic activity comparable to or greater than that of the marketed antibiotic Zyvox linezolid. In four mouse models of lung infection, the lead fluorocycline showed efficacy comparable to or greater than that of Zyvox. Next steps could include additional preclinical testing of the compounds.</p> <p>Pfizer Inc. markets Zyvox for multiple bacterial infections.</p> <p>Tetraphase Pharmaceuticals Inc. has the 8-azatetracycline TP-434 in Phase II testing to treat bacterial infection.</p> <p>SciBX 5(2); doi:10.1038/scibx.2012.44 Published online Jan. 12, 2012</p>	Patent application filed; licensing status unavailable	<p>Clark, R.B. <i>et al. J. Med. Chem.</i>; published online Dec. 9, 2011; doi:10.1021/jm201467r</p> <p>Contact: Roger B. Clark, Tetraphase Pharmaceuticals Inc., Watertown, Mass. e-mail: rclark@tphase.com</p>